Hepatocellular injury and the mortality risk among patients with COVID-19: A retrospective cohort study

Table 2 Odds ratios of liver injury associated mortality and 95% confidence intervals by aspartate aminotransferase categories

	Unadjusted			Model 1 (adjusted for age and sex)			Model 2
AST	OR	CI	P value	OR	CI	P value	OR	CI	P value
< 40	Ref			Ref			Ref
40-80	6.1	2.5-14.7	0.0001	4.8	1.9-12.1	0.001	10.8	2.5-40.9	0.001
> 80	6.1	1.5-25.5	0.01	2.9	0.6-13.7	0.18	12.8	1.5-93.4	0.02
						Covariates
						Age
						< 40	Ref
						40-60	1.1	0.2-6.2		0.9
						> 60	6.3	1.2-33.1		0.03
						Sex	1.1	0.4-3.7		0.7
						DM	5.7	1.0-31.7		0.04
						HTN	0.3	0.1-2.0		0.2
						IHD	5.0	0.7-37.3		0.1
						COPD	0.7	0.1-3.6		0.6
						DCI
						0-1
						2-3	0.90	0.090-9.600		0.07
						> 3	0.200	0.001-25.600		0.5
						ALT
						< 40	Ref
						40-80	0.30	0.09-1.20		0.1
						> 80	0.10	0.02-1.20		0.07
						Albumin	0.8	0.2-2.5		0.7
						Bilirubin	17.2	0.9-312.8		0.05
						Ferritin	20.7	1.7-247.0		0.01
						Creatinine	1.8	0.6-5.8		0.3
						Obesity	3.3	0.9-11.4		0.06

Adjusted odds ratios for in-hospital mortality. Model adjusted for sex and age. Model 2 adjusted for age, sex. OR: Odds ratio; CI: Confidence interval; DCI: Deyo–Charlson index; DM: Diabetes mellites; HTN: Hypertension; IHD: Ischaemic heart disease; COPD: Chronic obstructive pulmonary disease; ALT: Alanine transferase; AST: Aspartate transferase, albumin, bilirubin, ferritin, creatinine and obesity.